Xeris Biopharma Director Bormann-Kennedy Executes Pre-Arranged Sale and Receives Equity Grants
Barbara-Jean Anne Bormann-Kennedy, a director at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), executed a series of equity transactions on June 4, 2026. The activity includes the sale of 16,000 shares through a pre-arranged trading plan, as well as the acquisition of restricted stock units and stock options granted by the company. These transaction…